Inpharma Weekly

, Volume 1176, Issue 1, pp 13–14 | Cite as

Elucidating mechanisms of tamoxifen resistance in breast cancer

  • Robert Carlson
Newsletter Article


Estrogen receptor (ER)-positive breast tumours are stimulated by estrogen, and so antiestrogenic therapy has become a fundamental adjuvant therapy for many women with this disease. Tamoxifen is the gold standard for antiestrogen drugs, but residual tumour cells have a knack of developing resistance to tamoxifen, leading to disease recurrence. Overcoming tamoxifen resistance was a major topic at the 21st Annual San Antonio Breast Cancer Symposium [ San Antonio, US; December 1998 ]. Evidence was presented showing that the nature of tamoxifen itself may be the problem, as it has both estrogen-agonist and -antagonist properties.


Breast Cancer Tamoxifen Tamoxifen Therapy Tamoxifen Resistance Residual Tumour Cell 

Copyright information

© Adis International Ltd 1999

Authors and Affiliations

  • Robert Carlson

There are no affiliations available

Personalised recommendations